Compare OGE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | GKOS |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.6B |
| IPO Year | 2009 | 2015 |
| Metric | OGE | GKOS |
|---|---|---|
| Price | $44.79 | $154.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $48.78 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 1.4M | 636.1K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | ★ 5.94 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $3,260,100,000.00 | $507,442,000.00 |
| Revenue This Year | $3.74 | $23.32 |
| Revenue Next Year | $1.42 | $27.43 |
| P/E Ratio | $184.50 | ★ N/A |
| Revenue Growth | 9.21 | ★ 32.33 |
| 52 Week Low | $41.70 | $73.16 |
| 52 Week High | $50.59 | $191.62 |
| Indicator | OGE | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 33.05 |
| Support Level | $42.12 | $145.78 |
| Resistance Level | $48.32 | $161.53 |
| Average True Range (ATR) | 0.71 | 7.06 |
| MACD | -0.14 | -2.33 |
| Stochastic Oscillator | 17.21 | 11.50 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.